Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study

Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study - Safety and efficacy of Enoxaparine sodium after oncogynecological surgical patients:phase 2 study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003246

Enrollment

100

Registered

2010-03-01

Start date

2010-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gynecological cancer

Interventions

low weight molecular heparin 2times per day 7-14 days

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: oncogynecological surgical patients

Exclusion criteria

Exclusion criteria: bleeder etc

Design outcomes

Primary

Measure	Time frame
incidence of bleeding event	—

Secondary

Measure	Time frame
incidence of venous thromboembolism	—

Countries

Japan

Contacts

Public ContactNobutaka Takahashi

shizuoka cancer center gynecology

n.takahashi@scchr.jp055-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026